ReviewMetabolites2017
Magnetic Resonance Spectroscopy for Detection of 2-Hydroxyglutarate as a Biomarker for IDH Mutation in Gliomas.
Review in Metabolites, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Interval brain imaging for adults with cerebral glioma.The Cochrane database of systematic reviews · 2019Pooled it
- Quantitative magnetic resonance imaging and radiogenomic biomarkers for glioma characterisation: a systematic review.The British journal of radiology · 2018Pooled it
- Metabolite ratiomics: Rapid diagnosis and classification of gliomas for intraoperative application during brain surgery.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Pediatric Diffuse High-Grade Gliomas: A Comprehensive Review Of Advanced Methods Of Diagnosis And Treatment.Current cancer drug targets · 2026Review
- From Inhibitors to PET: SAR-Based Development of [Journal of medicinal chemistry · 2025Article
- Neomorphic IDH Heterodimer Mutants: An Underestimated Point in Cancer Pathogenesis.Current cancer drug targets · 2025Review
- Detection of IDH mutation in glioma by desorption electrospray ionization (DESI) tandem mass spectrometry.Scientific reports · 2024Article
- Rapid detection of IDH mutations in gliomas by intraoperative mass spectrometry.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- The interplay mechanism between IDH mutation, MGMT-promoter methylation, and PRMT5 activity in the progression of grade 4 astrocytoma: unraveling the complex triad theory.Oncology research · 2024Article
- Untangling the web of glioblastoma treatment resistance using a multi-omic and multidisciplinary approach.The American journal of the medical sciences · 2023Review
- Review
- Label-Free Chemically and Molecularly Selective Magnetic Resonance Imaging.Chemical & biomedical imaging · 2023Review
- Mutant Isocitrate Dehydrogenase 1 Expression Enhances Response of Gliomas to the Histone Deacetylase Inhibitor Belinostat.Tomography (Ann Arbor, Mich.) · 2023Article
- Exceptionally rare IDH1-mutant adult medulloblastoma with concurrent GNAS mutation revealed by in vivo magnetic resonance spectroscopy and deep sequencing.Acta neuropathologica communications · 2023Article
- Deep-learning and conventional radiomics to predictFrontiers in oncology · 2023Article
- Differential metabolic alterations in IDH1 mutant vs. wildtype glioma cells promote epileptogenesis through distinctive mechanisms.Frontiers in cellular neuroscience · 2023Review
- Noninvasive Determination of the IDH Status of Gliomas Using MRI and MRI-Based Radiomics: Impact on Diagnosis and Prognosis.Current oncology (Toronto, Ont.) · 2022Review
- Diagnostic and Prognostic Value of pH- and Oxygen-Sensitive Magnetic Resonance Imaging in Glioma: A Retrospective Study.Cancers · 2022Article
- Advanced multiparametric MRI-based scoring for isocitrate dehydrogenase mutation prediction of gliomas.Polish journal of radiology · 2022Article
- Mitochondrial DNA Alterations in Glioblastoma (GBM).International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mutations in the isocitrate dehydrogenase (IDH)1/2 genes are highly prevalent in gliomas and have been suggested to play an important role in the development and progression of the disease. Tumours harbouring these mutations exhibit a significant alteration in their metabolism resulting in the aberrant accumulation of the oncometabolite 2-hydroxygluarate (2-HG). As well as being suggested to play an important role in tumour progression, 2-HG may serve as a surrogate indicator of IDH status through non-invasive detection using magnetic resonance spectroscopy (MRS). In this review, we describe the recent efforts in developing MRS methods for detection and quantification of 2-HG in vivo and provide an assessment of the role of the 2-HG in gliomagenesis and patient prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.